Engineering teams meticulously document component details but often fail to apply the same rigor to assembly specifications. This oversight becomes a major source of failure, especially when transitioning from pilot lines to high-volume manufacturing.

When scaling to production, the biggest pitfall is the implicit knowledge held by the original design team who unconsciously fill procedural gaps. To succeed, involve someone with a manufacturing background but no project history to rigorously review procedures and expose these unstated assumptions before scaling.

A great molecule isn't enough to attract investment. Scientists must demonstrate they've considered manufacturing from day one. Designing a robust process that fits a consistent GMP facility shows investors that the project is not just a scientific curiosity but a viable path to a scalable product.

In high-stakes regulated fields, documentation like FMEAs is not red tape. It's a critical tool for understanding failure modes, mitigating risks, and ensuring product viability and patient safety, especially for a startup where one recall can be fatal.

To ensure a smooth transition from development to production, an operations or manufacturing SME must be part of the design process from the start. Otherwise, products are developed without manufacturability in mind, leading to expensive, reactive fixes and subjective quality control during scale-up.

A process that seems simple in a development lab is often not viable in a strict GMP manufacturing environment. To create truly manufacturable therapies, process development scientists need direct, hands-on exposure to GMP constraints and workflows to avoid significant rework and delays.

Companies often mistakenly expect their CDMO to fill strategic gaps. A CDMO's role is to execute the plan provided. Handing over an incomplete process is a 'wish,' not a tech transfer, and forces them to improvise in ways that may not align with your regulatory or commercial goals.

In bioprocessing, it is more efficient to design a development process that accommodates the constraints of the manufacturing facility. Forcing a plant to adapt to a rigid process is difficult and costly. This includes making early, scalable choices about materials like chromatography resins to ensure a smooth tech transfer.

The initial stage of process validation (PV Stage 1), which justifies all process limits and control strategies, is a significant but necessary resource commitment. Management often underestimates this phase, making it a difficult internal sell despite being a regulatory requirement for proving process control.